These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21960854)

  • 1. A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.
    Keshavarzian A; Mayer L; Salzberg B; Garone M; Finkelstein W; Cappa J; Brand M; Hain J; Zelinger D; Hegedus R; Diamond RH; Campbell U; Lane C; Stang P; Watson J; Cominelli F
    Gastroenterol Hepatol (N Y); 2007 May; 3(5):381-90. PubMed ID: 21960854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
    Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence and management of infusion reactions to infliximab: a large center experience.
    Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
    Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
    Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T; Rawlins M; Kozarek R; France R; Patterson D
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
    Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
    Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Infliximab Infusion in the Pediatric Population.
    Munsel EJ; Bryan PJ; Binstadt BA; Bullock D; Correll CK; Downs EM; Hobday PM; Larson-Nath C; Sudel B; Vehe RK
    J Pediatr Pharmacol Ther; 2020; 25(8):705-708. PubMed ID: 33214781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience].
    Botsios C; Ostuni P; Todesco S
    Reumatismo; 2005; 57(1):44-51. PubMed ID: 15776146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
    Kugathasan S; Levy MB; Saeian K; Vasilopoulos S; Kim JP; Prajapati D; Emmons J; Martinez A; Kelly KJ; Binion DG
    Am J Gastroenterol; 2002 Jun; 97(6):1408-14. PubMed ID: 12094858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions.
    Ducharme J; Pelletier C; Zacharias R
    Frontline Gastroenterol; 2011 Oct; 2(4):249-254. PubMed ID: 28839619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.